 Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 7 | 7 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 5 | 5 | | 2005 | 0 | 8 | 8 | | 2006 | 0 | 10 | 10 | | 2007 | 0 | 9 | 9 | | 2008 | 0 | 12 | 12 | | 2009 | 0 | 23 | 23 | | 2010 | 1 | 29 | 30 | | 2011 | 7 | 15 | 22 | | 2012 | 12 | 6 | 18 | | 2013 | 20 | 19 | 39 | | 2014 | 13 | 13 | 26 | | 2015 | 8 | 9 | 17 | | 2016 | 8 | 7 | 15 | | 2017 | 13 | 15 | 28 | | 2018 | 7 | 18 | 25 | | 2019 | 32 | 16 | 48 | | 2020 | 31 | 23 | 54 | | 2021 | 23 | 39 | 62 | | 2022 | 11 | 42 | 53 | | 2023 | 6 | 46 | 52 | | 2024 | 49 | 13 | 62 | | 2025 | 42 | 15 | 57 | | 2026 | 18 | 8 | 26 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Lee Batlevi C, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang ML. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026 Aug 06; 148(6):682-692.
-
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Álvarez-Fernández C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gómez de Liaño A. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23; 395(4):338-348.
-
Borden LE, Cosgrove CM, Washington CR, Thomas SM, Haight PJ, Brown A, Powell K, Harsono A, Mullen M, Crafton S, Jackson AL, Corr BR, Wright JD, Konecny GE, Bae-Jump VL, Podwika SE, Smitherman C, Maxwell GL, Backes FJ, Pothuri B, Ko EM, Arend RC, Thaker PH, Duska LR, Secord AA, Moore KN. MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2026 Aug; 211:231-237.
-
Pittock SJ, Barnett MH, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Pathak R, Allen K, Parks B, Kim HJ. Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Final CHAMPION-NMOSD Results. Neurol Neuroimmunol Neuroinflamm. 2026 Sep; 13(5):e200609.
-
Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME. Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2026 Aug; 11(8):672-688.
-
Benedetto A, Boguniewicz M, Fonacier L, Silverberg J, Abuabara K, Ong PY. Atopic dermatitis Yardstick: A new era of topical and systemic treatments. Ann Allergy Asthma Immunol. 2026 Aug; 137(2):252-265.
-
Rosenberg JE, O'Donnell PH, Petrylak DP, Flaig TW, Hoimes CJ, Gupta S, Mar N, Friedlander TW, Tagawa ST, Bilen MA, Brown JR, McKay RR, Merchan JR, Srinivas S, Gorla S, Moreno BH, Davis G, Wirtz HS, Zhu Y, Milowsky MI. EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. ESMO Open. 2026 Jun; 11(6):107700.
-
Stabell AC, Lee S, Park DJ, Lavine CL, Espinosa SM, Baharani VA, Patejak R, Nussenzweig MC, Caskey M, Seaman MS, Bieniasz PD, Hatziioannou T. Diverse paths to broadly neutralizing antibody escape among HIV-1 strains. Nat Microbiol. 2026 Jun; 11(6):1573-1584.
-
Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J. Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. J Clin Oncol. 2026 06 20; 44(18):1697-1708.
-
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|